Latest Conference Articles

December 13th 2013, 9:03am

San Antonio Breast Cancer Symposium

A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.

December 13th 2013, 8:52am

San Antonio Breast Cancer Symposium

Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

December 13th 2013, 8:00am

ASH Annual Meeting and Exposition

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

December 12th 2013, 5:31pm

San Antonio Breast Cancer Symposium

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

December 12th 2013, 5:03pm

San Antonio Breast Cancer Symposium

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

December 12th 2013, 3:13pm

ASH Annual Meeting and Exposition

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

December 12th 2013, 1:50pm

San Antonio Breast Cancer Symposium

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

December 12th 2013, 11:36am

San Antonio Breast Cancer Symposium

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

December 12th 2013, 8:20am

San Antonio Breast Cancer Symposium

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

December 12th 2013, 7:39am

San Antonio Breast Cancer Symposium

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

December 12th 2013, 6:24am

San Antonio Breast Cancer Symposium

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

December 12th 2013, 6:11am

San Antonio Breast Cancer Symposium

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

December 11th 2013, 5:34pm

ASH Annual Meeting and Exposition

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

December 11th 2013, 4:02pm

San Antonio Breast Cancer Symposium

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.

December 11th 2013, 2:59pm

San Antonio Breast Cancer Symposium

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

December 11th 2013, 9:14am

ASH Annual Meeting and Exposition

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

December 10th 2013, 5:51pm

ASH Annual Meeting and Exposition

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

December 10th 2013, 2:56pm

ASH Annual Meeting and Exposition

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

December 10th 2013, 12:51pm

ASH Annual Meeting and Exposition

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

December 10th 2013, 12:11pm

ASH Annual Meeting and Exposition

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.